American Journal of Clinical Dermatology

, Volume 2, Issue 1, pp 1–6 | Cite as

A Role for Leukotriene Antagonists in Atopic Dermatitis?

  • Sumitra Chari
  • Lesley Clark-Loeser
  • Jerome Shupack
  • Ken WashenikEmail author
Leading Article


Atopic dermatitis is a chronic, relapsing skin condition that affects over 2% of the population. The pathophysiology of this disease is not completely understood, but immunologic abnormalities and the subsequent release of inflammatory mediators play a central role. Treatment with glucocorticoids has long been the standard of care, but their use is limited by their adverse effect profile. Leukotrienes (LTB4, LTC4, LTD4, and LTE4) are metabolites of arachidonic acid produced through the 5-lipoxygenase pathway. They play an important role in inflammatory and atopic conditions. LT modulating agents have been used with success in asthma. Recently, there has been increased interest in the potential utility of LT antagonists in atopic dermatitis. In vitro and in vivo data have demonstrated that LTs may play a key role in atopic dermatitis. The 2 different types of LT-modulating agents are 5-lipoxygenase inhibitors and LT receptor antagonists. Since the 5-lipoxygenase inhibitor acts at an earlier step in the LT synthetic pathway, it has the ability to alter the production of all the LTs, including LTB4, while the receptor antagonists target only the cysteinyl LTs, LTC4, LTD4, and LTE4. This reduction of LTB4 activity may point to a therapeutic advantage in using LT synthesis inhibitors as opposed to LT receptor antagonists for atopic dermatitis. Clinical evidence of the use of LT agents in atopic dermatitis is limited, but initial results have been promising and these agents may one day serve as corticosteroid-sparing treatments for atopic dermatitis.


Atopic Dermatitis Allergic Rhinitis Montelukast LTB4 Zafirlukast 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Champion R.H., Parish W.E. Atopic dermatitis. In: Rook A., Wilkinson D.S., Ebling F.J.G., editors. Textbook of dermatology. Oxford: Blackwell Scientific Publications, 1986: 419–434Google Scholar
  2. 2.
    Leung D.Y.M., Tharp M., Boguniewicz M. Atopic dermatitis. In: Freedberg I., Eisen A.Z., Wolff K., editors. Fitzpatrick’s dermatology in general medicine. New York: McGraw-Hill, 1999: 1464–1480Google Scholar
  3. 3.
    Koro O., Furutani K., Hide M., et al. Chemical mediators in atopic dermatitis: involvement of leukotriene B4 released by a type I allergic reaction in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1999 Apr; 103 (4): 663–670PubMedCrossRefGoogle Scholar
  4. 4.
    Hanifin J., Chan S.C. Diagnosis and treatment of atopic dermatitis. Dermatol Ther 1996; 1: 9–18Google Scholar
  5. 5.
    Ikai K., Imamura S. Role of eicosanoids in the pathogenesis of atopic dermatitis. Prostaglandins Leukot Essent Fatty Acids 1993 Jun; 48 (6): 409–416PubMedCrossRefGoogle Scholar
  6. 6.
    Horwitz R.J., McGill K.A., Busse W.W. The role of leukotriene modifiers in the treatment of asthma. Am J Respir Crit Care Med 1998 May; 157 (5 Pt 1): 1363–1371PubMedGoogle Scholar
  7. 7.
    Busse W.W. Leukotrienes and inflammation. Am J Respir Crit Care Med 1998 Jun; 157 (6 Pt 2): S210–S213; discussion S247-8Google Scholar
  8. 8.
    Dahlen S.E. Leukotriene receptors. Clin Rev Allergy Immunol 1999 spring–summer; 17 (1–2): 179–191PubMedCrossRefGoogle Scholar
  9. 9.
    Songzhu A., Goetzl E.J. Lipid mediators of hypersensitivity and inflammation. In: Middleton E., Ellis E.F., Yunginger J.W., editors. Allergy: principles and practice. St. Louis: Mosby-Year Book, 1998: 168–182 (C14)Google Scholar
  10. 10.
    Fischer A.R., Drazen J.M. Antileukotriene drugs in the treatment of asthma. In: Middleton E., Ellis E.F., Yunginger J.W., editors. Allergy: principles and practice. St. Louis: Mosby-Year Book, 1998: 678–684 (C49)Google Scholar
  11. 11.
    McGill K.A., Busse W.W. Zileuton. Lancet 1996 Aug 24; 348 (9026): 519–524PubMedCrossRefGoogle Scholar
  12. 12.
    Dahlen B., Zetterstrom O., Bjorck T., et al. The leukotriene-antagonist ICI-204,219 inhibits the early airway reaction to cumulative bronchial challenge with allergen in atopic asthmatics. Eur Respir J 1994 Feb; 7 (2): 324–331PubMedCrossRefGoogle Scholar
  13. 13.
    Soter N.A., Lewis R.A., Corey E.J., et al. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol 1983 Feb; 80 (2): 115–119PubMedCrossRefGoogle Scholar
  14. 14.
    Ikai K., Okano H., Sakamoto Y., et al. Leukotriene A4 hydrolase in human skin and peripheral leukocytes. In: Abstracts of 8th International Congress of Immunology, Hungary, 1992: 454Google Scholar
  15. 15.
    Neuber K., Hilger R.A., Konig W. Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis. Immunology 1991; 73: 83–87PubMedGoogle Scholar
  16. 16.
    Ruzicka T., Ring J. Enhanced releasability of prostaglandin E2 and leukotrienes B4 and C4 from leukocytes of patients with atopic eczema. Acta Dermatovener (Stockholm) 1987; 67: 469–475Google Scholar
  17. 17.
    Fogh K. Herlin T., Kragballe K. Eicosanoids in skin of patients with atopic dermatitis: prostaglandin E2 and leukotriene B4 are present in biologically active concentrations. J Allergy Clin Immunol 1989 Feb; 83 (2 Pt 1): 450–455PubMedCrossRefGoogle Scholar
  18. 18.
    Ruzicka T., Simmet T., Peskar B.A., et al. Skin levels of arachidonic acid-derived inflammatory mediators and histamine in atopic dermatitis and psoriasis. J Invest Dermatol 1986 Feb; 86 (2): 105–108PubMedCrossRefGoogle Scholar
  19. 19.
    Sansom J.E., Taylor G.W., Dollery C.T., et al. Urinary leukotriene E4 levels in patients with atopic dermatitis. Br J Dermatol 1997 May; 136 (5): 790–791PubMedCrossRefGoogle Scholar
  20. 20.
    Fauler J., Neumann C., Tsikas D., et al. Enhanced synthesis of cysteinyl leukotrienes in atopic dermatitis. Br J Dermatol 1993 Jun; 128 (6): 627–630PubMedCrossRefGoogle Scholar
  21. 21.
    Talbot S.F., Atkins P.C., Goetzl E.J., et al. Accumulation of leukotriene C4 and histamine in human allergic skin reactions. J Clin Invest 1985; 76: 650–656PubMedCrossRefGoogle Scholar
  22. 22.
    Nakayama J., Kiryu H., Hori Y. Leukotriene B4 in patients with atopic dermatitis and other skin diseases: changes by an anti-allergic agent, azelastine hydrochloride. In: Proceeding of the 7th Korea-Japan Joint Meeting of Dermatology, Korea, 1991: 388–397Google Scholar
  23. 23.
    Spector S., Tan R.A. Antileukotrienes in chronic urticaria. J Allergy Clin Immunol 1998 Apr; 101 (4 Pt 1): 572PubMedCrossRefGoogle Scholar
  24. 24.
    Carucci J.A., Washenik K., Weinstein A., et al. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998 Jul; 134 (7): 785–786PubMedCrossRefGoogle Scholar
  25. 25.
    Woodmansee D.P., Simon R.A. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999 Dec; 83 (6 Pt 1): 548–5452PubMedCrossRefGoogle Scholar
  26. 26.
    Van Pelt J.P., De Jong E.M., Seijer M.M., et al. Investigation of a novel and specific leukotriene B4 receptor antagonist in the treatment of stable plaque psoriasis. Br J Dermatol 1998 Sep; 139 (3): 396–402PubMedCrossRefGoogle Scholar
  27. 27.
    Yanase D.J., David-Bajar K.M. The leukotriene antagonist montelukast as a therapeutic agent for atopic dermatitis. In: 58th Annual Meeting of American Academy of Dermatology: 2000 Mar 10–15. Poster abstract book. San Francisco: American Academy of Dermatology, 2000Google Scholar
  28. 28.
    Wenzel S.E., Kamada A.K. Zileuton: the first 5-lipoxygenase inhibitor for the treatment of asthma. Ann Pharmacother 1996 Jul–Aug 30 (7–8): 858–864PubMedGoogle Scholar

Copyright information

© Adis International Limited 2001

Authors and Affiliations

  • Sumitra Chari
    • 1
  • Lesley Clark-Loeser
    • 1
  • Jerome Shupack
    • 1
  • Ken Washenik
    • 1
    Email author
  1. 1.The Ronald O. Perelman Department of DermatologyNYU School of MedicineNew YorkUSA

Personalised recommendations